| Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease MJ Casanova, M Chaparro, E Domenech, M Barreiro-de Acosta, ... Official journal of the American College of Gastroenterology| ACG 108 (3 …, 2013 | 263 | 2013 |
| Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease MJ Casanova, M Chaparro, B Molina, O Merino, R Batanero, ... Journal of Crohn's and Colitis 11 (12), 1430-1439, 2017 | 192 | 2017 |
| Long-term safety ofin uteroexposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study M Chaparro, A Verreth, T Lobaton, E Gravito-Soares, M Julsgaard, ... Official journal of the American College of Gastroenterology| ACG 113 (3 …, 2018 | 182 | 2018 |
| Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study MJ Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, ... Official journal of the American College of Gastroenterology| ACG 112 (1 …, 2017 | 121 | 2017 |
| Liver disease and erythropoietic protoporphyria: a concise review MJ Casanova-González, M Trapero-Marugán, EA Jones, R Moreno-Otero World journal of gastroenterology: WJG 16 (36), 4526, 2010 | 94 | 2010 |
| Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry M Chaparro, A Garre, F Mesonero, C Rodríguez, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 15 (1), 35-42, 2021 | 81 | 2021 |
| Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study M Chaparro, A Garre, A Núñez Ortiz, MT Diz-Lois Palomares, ... Journal of clinical medicine 10 (13), 2885, 2021 | 75 | 2021 |
| Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study M Mañosa, M Calafat, R De Francisco, C García, MJ Casanova, P Huelín, ... Alimentary pharmacology & therapeutics 47 (5), 605-614, 2018 | 74 | 2018 |
| Prevalence and factors associated with fatigue in patients with inflammatory bowel disease: a multicentre study C Chavarría, MJ Casanova, M Chaparro, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 13 (8), 996-1002, 2019 | 71 | 2019 |
| Current concepts on microscopic colitis: evidence‐based statements and recommendations of the Spanish Microscopic Colitis Group F Fernández‐Bañares, MJ Casanova, Y Arguedas, B Beltrán, D Busquets, ... Alimentary Pharmacology & Therapeutics 43 (3), 400-426, 2016 | 70* | 2016 |
| Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry M Chaparro, A Garre, M Iborra, M Sierra-Ausín, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 15 (11), 1846-1851, 2021 | 65 | 2021 |
| Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida registry MJ Casanova, M Chaparro, M Mínguez, E Ricart, C Taxonera, ... Inflammatory Bowel Diseases 26 (4), 606-616, 2020 | 48 | 2020 |
| Adalimumab or infliximab for the prevention of early postoperative recurrence of Crohn disease: results from the ENEIDA registry F Cañete, M Mañosa, MJ Casanova, RC González-Sueyro, J Barrio, ... Inflammatory bowel diseases 25 (11), 1862-1870, 2019 | 41 | 2019 |
| Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease I Rodríguez-Lago, JD Hoyo, A Perez-Girbes, A Garrido-Marín, ... United European gastroenterology journal 8 (9), 1056-1066, 2020 | 32 | 2020 |
| Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry X Andújar, C Loras, B González, M Socarras, V Sanchiz, M Boscà, ... Surgical Endoscopy 34, 1112-1122, 2020 | 32 | 2020 |
| Prediction of relapse after anti–tumor necrosis factor cessation in Crohn’s disease: individual participant data meta-analysis of 1317 patients from 14 studies RWM Pauwels, CJ van der Woude, D Nieboer, EW Steyerberg, ... Clinical Gastroenterology and Hepatology 20 (8), 1671-1686. e16, 2022 | 29 | 2022 |
| EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain M Chaparro, M Barreiro-de Acosta, JM Benítez, JL Cabriada, ... Therapeutic advances in gastroenterology 12, 1756284819847034, 2019 | 28 | 2019 |
| Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease MJ Casanova, M Chaparro, S Martínez, I Vicuña, JP Gisbert Journal of Crohn's and Colitis 6 (10), 1034-1037, 2012 | 28 | 2012 |
| Poor sensitivity of fecal gluten immunogenic peptides and serum antibodies to detect duodenal mucosal damage in celiac disease monitoring EJ Laserna-Mendieta, MJ Casanova, Á Arias, L Arias-González, ... Nutrients 13 (1), 98, 2020 | 20 | 2020 |
| Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study MJ Casanova, M Chaparro, Ó Nantes, JM Benítez, M Rojas‐Feria, ... Alimentary Pharmacology & Therapeutics 53 (12), 1277-1288, 2021 | 19 | 2021 |
